Air/liquid interface cultures for alveolar type II cell differentiation
Air/liquid interface cultures for alveolar type II cell differentiation
批准号:
8279217
负责人:
ROBERT James MASON
金额:
$19.81万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2014-06-30
关键词:
ABCA3 geneADD-1 proteinAcute Lung InjuryAcyltransferaseAddressAdultAdult Respiratory Distress SyndromeAirAlveolarApicalAreaBreathingCCAAT-Enhancer-Binding ProteinsCell Culture TechniquesCell Differentiation processCell RespirationCell physiologyCellsCitratesComplexCulture MediaCytoplasmDevelopmentDiffusionEpithelialExcisionFatty AcidsFatty-acid synthaseGasesGene Expression RegulationGene ProteinsGene TargetingGenesGenomicsGoalsGrantHumanImpairmentLeadLipidsLiquid substanceLungLung diseasesLysophosphatidylcholinesMediatingMetabolicMitochondriaNuclearOxygenPDPK1 genePathway interactionsPeroxisome Proliferator-Activated ReceptorsPhospholipidsPneumoniaProcessProcollagen-Proline DioxygenaseProductionProteinsPulmonary EdemaPulmonary SurfactantsRegulationRodentRoleSLC2A1 geneSRE-1 binding proteinStearoyl-CoA DesaturaseSystemType I Epithelial Receptor CellType II Epithelial Receptor CellVascular Endothelial Growth Factorsalveolar type II cellbasedeacylationdensityfactor Chuman FRAP1 proteinhypoxia inducible factor 1improvedin vivoinsightlipid biosynthesisnew therapeutic targetnovelresearch studysurfactanttissue culturetranscription factor
中文摘要
描述(由申请人提供):已知肺表面活性物质对气体交换和维持小气道通畅至关重要。然而,成人肺中表面活性剂产生的调控尚不完全清楚。目前还没有已知的药理学方法来增加体内内源性表面活性剂的产生来治疗肺部疾病。我们最近重新研究了在II型细胞原代培养中使用气/液界面培养(无根尖液)。我们发现,快速添加根尖液(<48 h)可降低表面活性剂蛋白水平,快速去除根尖液(<48 h)可恢复表面活性剂蛋白水平。本R21基金的目的是发现这种效应的机制。我们认为这一机制是由脯氨酰羟化酶2 (PHD2)的氧感应作用引起的,其作用是由HIF1a介导的。我们发现,在潜水培养中,核HIF1a和HIF2增加,HIF反应基因增加,这种效应被HIF稳定剂DMOG复制,并且这种效应被补充氧阻断。下游的改变可能包括抑制两个关键转录因子C/EBPa和SREBP-1。然而,我们注意到其他途径也可能参与其中,我们将检查TTF1, FOXA2, mTOR, PPAR?和AMPK靶基因在微阵列实验中的分析。我们最初的重点将放在HIF1a、C/EBP1和SREBP-1c应答基因上,因为它们很可能参与其中。我们已经大大改进了II型细胞培养,因此本提案中的所有研究都将是人类II型细胞。我们将讨论表面活性剂蛋白和磷脂的合成。我们认为,基于溶血磷脂酰胆碱酰基转移酶(LPCAT1)基因表达的调控,DPPC在人细胞中的去酰基-酰化重塑通路的活性低于啮齿动物细胞。本研究的目的是确定成人II型细胞中表面活性剂产生的调节。这项研究还表明,持续的肺水肿会损害I型细胞的功能,并为急性肺损伤中使用补充氧提供了另一个理由。
英文摘要
DESCRIPTION (provided by applicant): Pulmonary surfactant is known to be critical for gas exchange and for maintaining patency of small airways. However, regulation of surfactant production in the adult lung is not completely understood. There is currently no known pharmacologic means to increase endogenous surfactant production in vivo for the treatment of lung diseases. We recently revisited the use of air/liquid interface cultures (no apical fluid) in the primary culture of type II cells. We found that the addition of apical fluid rapidly (<48 h) reduces surfactant protein levels and removal of all apical fluid rapidly (<48 h) restores surfactant protein levels. The purpose of this R21 grant is to discover the mechanism for this effect. We propose that the mechanism is oxygen sensing by prolyl hydroxylase 2 (PHD2) and that the effect is HIF1a mediated. We find that in submerged cultures there is an increase in nuclear HIF1a and HIF2, an increase in HIF responsive genes, the effect is reproduced by the HIF stabilizer, DMOG, and that the effect is blocked by supplemental oxygen. The downstream alterations likely include inhibiting two key transcription factors C/EBPa and SREBP-1. However, we are mindful that other pathways are also likely involved, and we will examine TTF1, FOXA2, mTOR, PPAR? and AMPK target genes in the analyses of the microarray experiments. Our initial focus will be on HIF1a, C/EBP1, and SREBP-1c responsive genes, since they are likely to be involved. We have significantly improved our type II cell cultures so all the studies in this proposal will be human type II cells. We will address both surfactant protein and phospholipid synthesis. We believe that the deacylation-reacylation remodeling pathway for dipalmitoylphosphatidylchoine (DPPC) is less active in human cells than in rodent cells based on the regulation of gene expression of lysophosphatidylcholine acyltransferase (LPCAT1). The goal of this study is to define the regulation of surfactant production in adult human type II cells. This study should also indicate that sustained pulmonary edema will impair type I cell function and provide another reason for the use of supplemental oxygen in acute lung injury.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.bbrc.2014.09.060
发表时间:
2014-10-03
期刊:
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
影响因子:
3.1
作者:
[Ito, Yoko, Zernans, Rachel, Correll, Kelly, Yang, Ivana V., Ahmad, Aftab, Gao, Bifeng, Mason, Robert J.]
通讯作者:
Mason, Robert J.
Air/liquid interface cultures for alveolar type II cell differentiation
-
批准号:8191639
-
项目类别:
-
资助金额:$23.78万
-
财政年份:2011
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar type II cell innate immune response to influenza
-
批准号:8074270
-
项目类别:
-
资助金额:$24.72万
-
财政年份:2009
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar type II cell innate immune response to influenza
-
批准号:8063939
-
项目类别:
-
资助金额:$43.4万
-
财政年份:2009
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar type II cell innate immune response to influenza
-
批准号:8260411
-
项目类别:
-
资助金额:$43.38万
-
财政年份:2009
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar type II cell innate immune response to influenza
-
批准号:7679879
-
项目类别:
-
资助金额:$42.99万
-
财政年份:2009
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar type II cell innate immune response to influenza
-
批准号:7787530
-
项目类别:
-
资助金额:$43.84万
-
财政年份:2009
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar type II cell innate immune response to influenza
-
批准号:8456892
-
项目类别:
-
资助金额:$40.78万
-
财政年份:2009
-
负责人:ROBERT James MASON
-
依托单位:
DE PEDIATRIC COBRE: CELL SCIENCE CORE
-
批准号:7720949
-
项目类别:
-
资助金额:$26.53万
-
财政年份:2008
-
负责人:ROBERT James MASON
-
依托单位:
DE PEDIATRIC COBRE: CELL SCIENCE CORE
-
批准号:7610721
-
项目类别:
-
资助金额:$26.82万
-
财政年份:2007
-
负责人:ROBERT James MASON
-
依托单位:
DE PEDIATRIC COBRE: CELL SCIENCE CORE
-
批准号:7382170
-
项目类别:
-
资助金额:$26.61万
-
财政年份:2006
-
负责人:ROBERT James MASON
-
依托单位:
DE PEDIATRIC COBRE: CELL SCIENCE CORE
-
批准号:7171395
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2005
-
负责人:ROBERT James MASON
-
依托单位:
CORE--DE PEDIATRIC COBRE: CELL SCIENCE CORE
-
批准号:6973095
-
项目类别:
-
资助金额:$51.19万
-
财政年份:2004
-
负责人:ROBERT James MASON
-
依托单位:
Type II Pneumocyte Interactions with SARS-CoV
-
批准号:6797025
-
项目类别:
-
资助金额:$34.88万
-
财政年份:2003
-
负责人:ROBERT James MASON
-
依托单位:
Conference:Lung Surfactant:Cellular & Molecular Biology
-
批准号:6507112
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2002
-
负责人:ROBERT James MASON
-
依托单位:
Alveolar epithelium in pulmonary fibrosis
-
批准号:6616356
-
项目类别:
-
资助金额:$28.87万
-
财政年份:2002
-
负责人:ROBERT James MASON
-
依托单位:
SCOR: Pathobiology of Fibrotic Lung Disease
-
批准号:6785314
-
项目类别:
-
资助金额:$183.09万
-
财政年份:2001
-
负责人:ROBERT James MASON
-
依托单位:
SCOR: Pathobiology of Fibrotic Lung Disease
-
批准号:6912712
-
项目类别:
-
资助金额:$188.58万
-
财政年份:2001
-
负责人:ROBERT James MASON
-
依托单位:
SCOR: Pathobiology of Fibrotic Lung Disease
-
批准号:6573340
-
项目类别:
-
资助金额:$173.22万
-
财政年份:2001
-
负责人:ROBERT James MASON
-
依托单位:
SCOR: Pathobiology of Fibrotic Lung Disease
-
批准号:6346865
-
项目类别:
-
资助金额:$169.52万
-
财政年份:2001
-
负责人:ROBERT James MASON
-
依托单位:
SCOR: Pathobiology of Fibrotic Lung Disease
-
批准号:6616116
-
项目类别:
-
资助金额:$177.76万
-
财政年份:2001
-
负责人:ROBERT James MASON
-
依托单位: